Bristol-Myers Squibb Co (BMY) Stock’s -0.01% Decrease This Year: What’s the Story?
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and touched a low of $55.
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...
4d
Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...
First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback